ALHC vs. ALNY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and ALNY, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ALNY stands out with 38.15 billion USD in market value—about 12.58× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to ALNY’s calmer 0.17, suggesting both higher upside and downside potential.
| Symbol | ALHC | ALNY |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Alnylam Pharmaceuticals, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Biotechnology |
| CEO | Mr. John E. Kao | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| Price | 15.33 USD | 292.58 USD |
| Market Cap | 3.03 billion USD | 38.15 billion USD |
| Beta | 1.33 | 0.17 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | June 1, 2004 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and ALNY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and ALNY based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ALHC nor ALNY turned a profit—both carry negative P/E ratios of -32.75 and -140.68, underscoring continued losses that pressure their valuations.
- Analysts assign negative forward PEG ratios to both ALHC (-1.11) and ALNY (-38.16), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
- ALNY reports a negative Price-to-Free Cash Flow ratio of -506.05, showing a cash flow shortfall that could threaten its operational sustainability, while ALHC at 159.00 maintains positive cash flow.
| Symbol | ALHC | ALNY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | -140.68 |
| Forward PEG Ratio (TTM) | -1.11 | -38.16 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 16.25 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 328.68 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | -506.05 |
| EV-to-EBITDA (TTM) | -64.47 | -251.73 |
| EV-to-Sales (TTM) | 0.86 | 16.37 |
| EV-to-Free Cash Flow (TTM) | 136.01 | -509.80 |
Dividend Comparison
Neither ALHC nor ALNY currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALHC | ALNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and ALNY, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is highly leveraged (debt-to-equity ratio 11.28), elevating both potential gains and risks, compared to ALHC at 0.07, which maintains a steadier capital structure.
- Both ALHC and ALNY report negative interest coverage ratios (-2.98, -0.79), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
| Symbol | ALHC | ALNY |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 3.04 |
| Quick Ratio (TTM) | 1.69 | 2.98 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 11.28 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.31 |
| Interest Coverage Ratio (TTM) | -2.98 | -0.79 |